Zusammenfassung
Die Diagnose der ANCA-assoziierten Vaskulitiden (AAV) setzt sich mosaikartig aus dem
klinischen Befund, technischen Untersuchungsbefunden und der charakteristischen Histologie
zusammen. Die Diagnostik sollte sich an dem klinischen „Leitsymptom” orientieren.
Dabei hat sich für die weitergehenden Untersuchungen ein interdisziplinäres Vorgehen
mit den unterschiedlichen Fachrichtungen bewährt. Bei der Auswahl der Therapie wird
zwischen einer Remissionsinduktion und -erhaltung unterschieden. Cyclophosphamid gilt dabei als Standard-Therapie zur Remissionsinduktion,
während sich Azathioprin, MTX und Leflunomid generell zur Erhaltung der Remission
eignen. Die Etablierung einer stadienadaptierten Therapie hat wesentlich zur Verbesserung
der Langzeitprognose von Patienten mit AAV geführt.
Summary
The diagnosis of ANCA-associated vasculitides (AAV) consists of clinical symptoms,
results of technical procedures and a characteristical histology. The diagnostic workup
should focus on the prominent clinical symptoms and should involve an interdisciplinary
team of specialists. The therapy is divided into induction and maintenance treatment.
Cyclophosphamid remains standard therapy for the induction of remission, whereas azathioprine,
methotrexate and leflunomide are often used for maintenance therapy. The introduction
of a stage-adapted treatment has contributed to a significant improvement of the long-time
prognosis of patients with AAV.
Literatur
- 1
Aries P M, Hellmich B, Reinhold-Keller E, Gross W L.
High-dose intravenous azathioprine pulse treatment in refractory Wegener’s granulomatosis.
Rheumatology (Oxford).
2004;
43
1307-1308
- 2 AWMF, ÄZQ .Aus: Das Leitlinien-Manual von AWMF und ÄZQ,. Suppl 1 Z ärztl Fortbildung
Qual sich http://www.uni-Duesseldorf.de/AWMF/II/Iiman-05.pdf 2001 95: 41
- 3
Csernok E.
Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides.
Autoimmun Rev.
2003;
2
158-164
- 4
de Groot K, Jayne D, Tesar V, Savage C.
Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction
of remission in ANCA-associated systemic vasculitis (Abstract).
Kidney Blood Press Res.
2005;
28
195
- 5
de Groot K, Rasmussen N, Bacon P. et al .
Randomized trial of cyclophosphamide versus methotrexate for induction of remission
in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
Arthritis Rheum.
2005;
52
2461
- 6
Fauci A S, Haynes B F, Katz P, Wolff S M.
WegenerŽs granulomatosis: Prospective clinical and therapeutic experience with 85
patients for 21 years.
Ann Intern Med.
1983;
98
76-85
- 7
Hunder G G, Arend W P, Bloch D A. et al .
The American College of Rheumatology 1990 criteria for the classification of vasculitis
Introduction.
Arthritis Rheum.
1990;
33
1065-1067
- 8
Jayne D, Rasmussen N, Andrassy K. et al .
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil
cytoplasmic autoantibodies.
N Engl J Med.
2003;
349
36-44
- 9
Jennette J C, Falk R J, Andrassy K. et al .
Nomenclature of systemic vasculitides: the proposal of an international consensus
conference.
Arthritis Rheum.
1994;
37
187-192
- 10
Keogh K, Wylam M, Stone J, Specks U.
Induction of remission by B lymphocyte depletion in eleven patients with refractory
antineutrophil cytoplasmic antibody-associated vasculitis.
Arthritis Rheum.
2005;
52
262-268
- 11
Lamprecht P, Voswinkel J, Lilienthal T. et al .
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis.
Rheumatology (Oxford).
2002;
41
1303-1307
- 12
Mahr A, Pagnoux C, Cohen P. et al .
Treatment of ANCA-associated vasculitides: corticosteroids and pulse cyclophosphamide
followed by maintenance therapy with methotrexate or azathioprine: a prospective multicenter
randomized trial (Wegent) (Abstract).
Kidney Blood Press Res.
2005;
28
194
- 13
Metzler C, Fink C, Lamprecht P. et al .
Maintenance of remission with leflunomide in Wegener’s granulomatosis.
Rheumatology.
2004;
63
339-340
- 14
Reinhold-Keller E, Beuge N, Latza U. et al .
An interdisciplinary approach to the care of patients with Wegener’s granulomatosis:
long-term outcome in 155 patients.
Arthritis Rheum.
2000;
43
1021-1032
- 15
Savige J, Dimech W, Fritzler M. et al. International Group for Consensus Statement
on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) .
Addendum to the International Consensus Statement on testing and reporting of antineutrophil
cytoplasmic antibodies. Quality control guidelines, comments, and recommendations
for testing in other autoimmune diseases (Review).
Am J Clin Pathol.
2003;
120
312-318
- 16
Stone J H, Uhlfelder M L, Hellmann D B. et al .
Etanercept combined with conventional treatment in Wegener’s granulomatosis: a six-month
open-label trial to evaluate safety.
Arthritis Rheum.
2001;
44
1149-1154
Dr. med. Peer M. Aries
Rheumaklinik Bad Bramstedt, Klinik für Innere Medizin, Rheumatologie und Immunologie
Oskar-Alexander Straße 26
24572 Bad Bramstedt
Phone: 04192/90-2576
Fax: 04192/90-2389
Email: aries@rheuma-zentrum.de
